Test Price
1,200 AEDโ Home Collection Available
RET (NSCLC) Oncogene Analysis โ FISH Molecular Diagnostics
Executive Summary & Core Metrics
This advanced RET oncogene analysis for Non-Small Cell Lung Carcinoma (NSCLC) delivers definitive molecular diagnostics with 99.9% sensitivity via ISO-accredited Fluorescence In-Situ Hybridization (FISH) methodology. The test identifies actionable RET gene rearrangements in tumor tissue, guiding targeted tyrosine kinase inhibitor therapy selection per DHA precision medicine protocols. Secure medical courier solid tissue specimen retrieval is available for archival FFPE blocks and biopsy samples, with telephonic post-test clinical guidance provided by our oncology specialists.
Test Overview & Methodology
The RET (Rearranged during Transfection) Oncogene Analysis is a definitive molecular diagnostic test designed to detect gene rearrangements in tumor tissue from patients with Non-Small Cell Lung Cancer (NSCLC). Utilizing Fluorescence In-Situ Hybridization (FISH), this assay identifies actionable RET fusionsโcritical biomarkers that guide targeted tyrosine kinase inhibitor (TKI) therapy selection, directly influencing treatment efficacy and survival outcomes in the UAE oncology landscape per DHA precision medicine protocols. RET fusions occur in approximately 1-2% of NSCLC adenocarcinomas and are mutually exclusive with other driver alterations such as EGFR, ALK, and ROS1, making this test essential for comprehensive biomarker profiling.
| Feature | Our Test โ RET (NSCLC) FISH Analysis | Closest Alternative โ RET NGS Panel |
|---|---|---|
| Methodological Precision | Dual-color Break-apart FISH; direct visualization of gene rearrangement on tissue architecture | Next-Generation Sequencing (NGS); relies on extracted nucleic acid amplification |
| Diagnostic Sensitivity | 99.9% with ISO 9001:2015 Certified Protocol | Variable (85-95%); dependent on tumor cellularity and DNA quality |
| Turnaround Time | 7โ8 Days (Expedited UAE Delivery) | 10โ21 Days (Often batched; external laboratory referral) |
| Clinical Actionability | Directly aligns with DHA/MOHAP targeted therapy guidelines for Selpercatinib/Pralsetinib | May generate incidental findings of uncertain significance (VUS) requiring additional interpretation |
| Sample Requirement | Formalin-Fixed Paraffin-Embedded (FFPE) Tumor Tissue Block / Biopsy | FFPE tissue with โฅ20% tumor nuclei; risk of sample rejection due to low input |
Physician Insight & Safety Protocols
A clinical perspective from Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology (DHA Registration ID: 61713011) โ
"Identifying a RET rearrangement through FISH analysis provides a clear therapeutic roadmap for patients with advanced NSCLC. This biomarker directly informs the use of selective RET inhibitors that have demonstrated meaningful intracranial and systemic responses. Clinicians should interpret the FISH result alongside histopathologic grading, imaging response assessment, and the patient's overall functional status to optimize treatment sequencing and avoid unnecessary chemotherapy-related toxicity."
Clinical Advisory โ Result Interpretation & Therapeutic Decision-Making
Medication Stewardship & Clinical Correlation
A positive RET fusion result should never be interpreted in isolation. Therapeutic decisions involving RET-selective tyrosine kinase inhibitors require integration with the patient's complete clinical profile, including prior treatment history, organ function, and potential drug-drug interactions. Patients currently receiving systemic therapy should continue prescribed treatment until explicit guidance is provided by their treating oncologist. Abrupt discontinuation of existing therapy without medical supervision may lead to accelerated disease progression. The FISH result serves as a complementary data point within a comprehensive multidisciplinary evaluation.
Exclusion Criteria & Clinical Contraindications
- โข Inadequate Tissue Sample: Insufficient tumor cellularity (<50 viable tumor cells) or extensive necrosis renders FISH analysis unreliable. Repeat biopsy will be requested.
- โข Prior Decalcification Agents: Bone biopsy samples treated with strong acid decalcification compromise DNA integrity; formalin-fixed paraffin-embedded (FFPE) specimens must meet decalcification-free criteria as per DHA pathology guidelines.
- โข Pediatric/Minor Consent: Testing on individuals under 18 years requires explicit guardian consent and a registered DHA pediatric oncology consultation. Unauthorized pediatric testing is strictly prohibited.
- โข Emergency Clinical Signs: Patients experiencing acute hemoptysis, superior vena cava syndrome, or rapid neurological deterioration must seek immediate emergency care; this test is not a substitute for urgent oncologic intervention.
- โข Prescription Requirement: A valid Doctor's prescription is mandatory for this test. Routine RET analysis without a prescription is not applicable for patients undergoing surgical procedures, pregnant individuals, or those planning international travel as per UAE healthcare compliance regulations.
Patient FAQ & Clinical Guidance
1. What does a positive RET rearrangement result mean for my NSCLC treatment plan?
A positive RET rearrangement definitively identifies your tumor as harboring an actionable oncogenic driver, qualifying you for FDA-approved and DHA-recommended RET-selective tyrosine kinase inhibitors. This result transforms your treatment paradigm from conventional chemotherapy to precision-targeted agents such as Selpercatinib or Pralsetinib, which have demonstrated superior progression-free survival compared to multi-kinase inhibitors or platinum-based doublets. Your oncologist will integrate this finding with your performance status, metastatic burden, and comorbidities to tailor a personalized therapeutic regimen. Confirmation of RET fusion via FISH is the gateway biomarker; it does not predict intrinsic resistance mutations, which may be further evaluated through complementary sequencing if clinically indicated.
2. How long does it take to receive the RET FISH result in the UAE?
The standard turnaround time for RET FISH analysis in our UAE-based, ISO-certified laboratory is strictly 7 to 8 calendar days from specimen accessioning. This timeline encompasses histopathologic review, FISH hybridization, fluorescence microscopy interpretation by two independent clinical molecular pathologists, and final integrated reporting. Expedited processing for urgent clinical cases may be accommodated upon oncologist request; please contact our support line at +971 54 548 8731 before sample submission to arrange priority handling. Delays beyond 8 days are rare and typically attributable to inadequate tissue requiring re-cutting or re-hybridization, in which case the referring physician is notified within 48 hours.
3. Is a repeat biopsy required if my archived tumor block is more than two years old?
Archived formalin-fixed paraffin-embedded (FFPE) blocks stored under appropriate conditions retain sufficient DNA integrity for accurate RET FISH testing for up to five years, provided the tissue was adequately fixed initially. Our laboratory evaluates every submitted block for tumor content and DNA preservation before hybridization; if the sample fails pre-analytical quality checks due to excessive degradation or low tumor cellularity, a new biopsy may be recommended. We strongly advise against empirical re-biopsy solely for RET testing without prior assessment of the existing archival material, as this may delay care and expose patients to unnecessary procedural risks. Submit the available block first; our pathology team will issue a viability report within 24 hours of receipt.
UAE Regulatory & Data Privacy Adherence
Data Privacy & Legal Compliance Framework
All patient genomic data is processed in strict accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Genomic information is classified as sensitive personal data with enhanced security protocols and is never shared with third parties without explicit written consent. Clinical testing safety and patient consent protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring that every specimen is handled with the highest standards of care and confidentiality. Our laboratory operates under DHA Facility License Number 1143 and maintains full compliance with Dubai Healthcare City regulatory requirements.
Clinical & Logistical Metadata
| Test Name | RET (NSCLC) Oncogene Analysis โ FISH |
| Price (AED) | 1,200 AED |
| Turnaround Time | 7โ8 Calendar Days |
| Sample Type / Matrix | Formalin-Fixed Paraffin-Embedded (FFPE) Tumor Tissue Block / Biopsy Slides |
| Methodology Used | Dual-color Break-apart Fluorescence In-Situ Hybridization (FISH) |
| ICD-10-CM Code | C34.9, C34.00, C34.01, C34.02, C34.10, C34.11, C34.12, C34.2, C34.30, C34.31, C34.32, C34.8 |
| LOINC Code | 94356-4 |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians